What was Vimizim’s launch price (and what does “annual” mean)?
Vimizim (elosulfase alfa) had an initial U.S. launch price reported as $380,000 per year in 2014. That figure is the annual list-price cost stated for the drug at launch, not a one-time payment. [1]
Where does the $380,000 annual 2014 figure come from?
The $380,000 annual launch price for Vimizim in 2014 is cited in reporting that tracked the drug’s introduction and pricing. [1]
Is $380,000 the same as what patients pay?
The $380,000 figure is a drug’s list-price/launch price reference. The amount a patient actually pays depends on insurance coverage, negotiated discounts, copays, and patient-assistance programs, which are not specified in the launch-price reporting. [1]
If you meant the price for a different market or year
Pricing can differ by country and over time due to regulatory approvals, payer negotiations, and subsequent price changes. If you tell me the country (e.g., U.S. vs. EU) and the year, I can help locate the corresponding price figure.
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125397